|Table of Contents|

The Ki-67 expression change after neoadjuvant chemotherapy in triple negative breast cancer and the correlation with efficacy and prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 05
Page:
773-776
Research Field:
Publishing date:

Info

Title:
The Ki-67 expression change after neoadjuvant chemotherapy in triple negative breast cancer and the correlation with efficacy and prognosis
Author(s):
LIU Shihao1; ZHANG Xin2; HU Guoqing3; CUI Ruina4
1.The Sixth Department of General Surgery;2.Department of Ultrasound;3.Department of Radiology;4.Department of Neurology,the First Hospital of Handan City，Hebei Handan 056000,China.
Keywords:
triple negative breast cancer; neoadjuvant chemotherapy; Ki-67; prognosis
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2021.05.012
Abstract:
Objective:To investigate the relationship between the expression of Ki-67 and the efficacy and prognosis of neoadjuvant chemotherapy in triple negative breast cancer.Methods:We selected 70 cases of patients with TNBC from January 2013 to January 2018.Immunohistochemical method was used to detect the changes of the expression of Ki-67 of the NAC.According to the expression of Ki-67 change,the patients were divided into three groups,including low to high expression group,expression unchanged group and high to low expression group.Clinical pathology reaction of three groups of patients with NAC.Kaplan-Meier analysed survival curve.Results:49 patients achieved clinical remission after NAC.27 patients achieved pathological complete response（pCR).After NAC high to low expression group could obtain better clinical remission rate and pCR rate.The comparison results of the three groups showed that the differences were statistically significant（P＜0.05).The DFS in the low to high expression group,expression unchanged group and the high to low expression group,with statistically significant differences（P=0.001).There was no statistically significant difference in the comparison results of OS among the three groups（P=0.085).Conclusion:TNBC patients after NAC can change the expression of Ki-67,and patients with reduced Ki-67 expression may have better efficacy and prognosis.

References:

[1]FAN L,STRASSER-WEIPPL K,LI JJ,et al.Breast cancer in China［J］.Lancet Oncol,2014,15(7):279-289.
[2]BIANCHINI G,BALKO JM,MAYER IA,et al.Triple-negativebreast cancer:challenges and opportunities of a heteroge-neous disease［J］.Nat Rev Clin Oncol,2016,13(11):674-690.
[3]SYMMANS WF,WEI C,GOULD R,et al.Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype［J］.J Clin Oncol,2017,35(10):1049-1060.
[4]冯轲昕,王翔,王昕.增殖细胞核抗原Ki-67及其在新辅助化疗前后的变化与乳腺癌预后的关系［J］.癌症进展,2019,17(13):1494-1497. FENG KX,WANG X,WANG X.The relationship between proliferating cell nuclear antigen Ki-67 and its changes before and after neoadjuvant chemotherapy and the prognosis of breast cancer［J］.Cancer Progression,2019,17(13):1494-1497.
[5]ABUBAKAR M,ORR N,DALEY F,et al.Prognostic value of automated Ki-67 scoring in breast cancer:a centralised evaluation of 8088 patients from 10 study groups［J］.Breast Cancer Res,2016,18(1):104-108.
[6]DUFFAUD F,THERASSE P.New guidelines to evaluate the response to treatment in solid tumors［J］.Bull Cancer,2000,87(12):881-886.
[7]HU XC,ZHANG J,XU BH,et al.Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer（CBCSG006):a ran domised,open-label,multicentre,phase 3 trial［J］.Lancet Oncol,2015,16(4):436-446.
[8]修萌,张频.早期三阴性乳腺癌治疗模式及新辅助治疗研究进展［J］.肿瘤防治研究,2020,47(2):129-134. XIU M,ZHANG P.Research progress of early triple negative breast cancer treatment model and neoadjuvant therapy［J］.Cancer Prevention Research,2020,47(2):129-134.
[9]LIEDTIKE C,MAZOUNI C,HESS KR,et al.Response to neoadiuvanttherapy and long-term survival in patients with triple-negative breast cancer［J］.J Clin Oncol,2008,26(8):1275-1281.
[10]ZHAO Y,DONG X,LI R,et al.Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer［J］.Onco Targets Ther,2015,34(8):1511-1521.
[11]许董,陈德觀.乳腺癌中Ki-67的表达与新辅助化疗后肿瘤缓解率的相关性研究［D］.重庆:重庆医科大学,2013. XU D,CHEN DG.Study on the correlation between the expression of Ki-67 in breast cancer and the tumor remission rate after neoadjuvant chemotherapy［D］.Chongqing:Chongqing Medical University,2013.
[12]张彦收,唐甜甜,周涛.Ki-67表达水平检测在乳腺癌新辅助化疗疗效评估中的价值［J］.现代肿瘤医学,2017,25(4):2256-2259. ZHANG YS,TANG TT,ZHOU T.The value of Ki-67 expression level detection in evaluating the efficacy of neoadjuvant chemotherapy for breast cancer［J］.Modern Oncology,2017,25(4):2256-2259.
[13]叶国麟,杨劼,古卫权,等.Ki-67表达对三阴性乳腺癌新辅助化疗疗效影响［J］.河北医学,2013,19(6):832-834. YE GL,YANG X,GU WQ,et al.Effect of Ki-67 expression on the efficacy of neoadjuvant chemotherapy for triple negative breast cancer［J］.Hebei Medical Science,2013,19(6):832-834.
[14]DE AZAMBUJA E,CARDOSO F,DE CASTRO GJR,et al.Ki-67 as prognostic marker in early breast cancer:a meta-analysis of published studies in volving 12 155 patients［J］.Br J Cancer,2007,96(10):1504-1513.
[15]YAMAZAKI N,WADA N,YAMAUCHI C,et al.High expression of post-treament Ki-67 status is a risk factor for locoregional recur-rence following breast-coneseving surgery after neoadjuvant chemtherapy［J］.EJSO,2015,41(5):617-624.
[16]WANG RX,CHEN S,JIN X,et al.Value of ki-67 expression in triple-negative breasr cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin［J］.Sei Rep,2016,6(30):91-95.
[17]MONTANA E,BAGNARDI V,VIALE G,et al.Changes in pae and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherpy［J］.Amn Oncol,2015,26(2):307-313.

Memo

Memo:
邯郸市科技局项目（编号：1823208078ZC）
Last Update: 2021-01-29